ATE530575T1 - Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a - Google Patents

Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a

Info

Publication number
ATE530575T1
ATE530575T1 AT08762760T AT08762760T ATE530575T1 AT E530575 T1 ATE530575 T1 AT E530575T1 AT 08762760 T AT08762760 T AT 08762760T AT 08762760 T AT08762760 T AT 08762760T AT E530575 T1 ATE530575 T1 AT E530575T1
Authority
AT
Austria
Prior art keywords
demannosylated
hemophilia
patients
treatment
factor viii
Prior art date
Application number
AT08762760T
Other languages
English (en)
Inventor
Abdessatar Chtourou
Desmazes Sebastien Lacroix
Srinivas Kaveri
Suryasarathi Dasgupta
Jagaadeesh Bayry
Original Assignee
Lfb Biotechnologies
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Inst Nat Sante Rech Med filed Critical Lfb Biotechnologies
Application granted granted Critical
Publication of ATE530575T1 publication Critical patent/ATE530575T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT08762760T 2007-04-20 2008-04-21 Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a ATE530575T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290495A EP1985631A1 (de) 2007-04-20 2007-04-20 Entmannosierter rekombinanter Faktor VIII zur Behandlung von Patienten mit Hämophilie A
PCT/IB2008/001417 WO2008129422A1 (en) 2007-04-20 2008-04-21 Demannosylated recombinant factor vii for the treatment of patients with haemophilia a

Publications (1)

Publication Number Publication Date
ATE530575T1 true ATE530575T1 (de) 2011-11-15

Family

ID=38515425

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08762760T ATE530575T1 (de) 2007-04-20 2008-04-21 Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a

Country Status (15)

Country Link
US (1) US8802620B2 (de)
EP (2) EP1985631A1 (de)
JP (1) JP2010524453A (de)
KR (1) KR20100017142A (de)
CN (1) CN101970481A (de)
AR (1) AR066132A1 (de)
AT (1) ATE530575T1 (de)
AU (1) AU2008240663A1 (de)
BR (1) BRPI0810592A2 (de)
CA (1) CA2684834A1 (de)
DK (1) DK2150561T3 (de)
ES (1) ES2376022T3 (de)
PL (1) PL2150561T3 (de)
TW (1) TW200914608A (de)
WO (1) WO2008129422A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526151A (ja) * 2008-06-25 2011-10-06 バイエル・ヘルスケア・エルエルシー 低下した免疫原性を有する因子ｖｉｉｉ変異タンパク質
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
CN105452289A (zh) * 2013-06-12 2016-03-30 诺和诺德股份有限公司 适用于治疗血友病的化合物
WO2015059121A1 (en) 2013-10-22 2015-04-30 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MX388739B (es) * 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
MY189674A (en) * 2015-10-28 2022-02-24 Sangamo Therapeutics Inc Liver-specific constructs, factor viii expression cassettes and methods of use thereof
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
JP7244547B2 (ja) * 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
EP4211153A4 (de) * 2021-11-25 2023-11-01 Sichuan Real&Best Biotech Co., Ltd. Manipuliertes menschliches fvii1 mit erhöhter sekretionsfähigkeit und gerinnungsaktivität

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) * 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Also Published As

Publication number Publication date
EP2150561A1 (de) 2010-02-10
BRPI0810592A2 (pt) 2014-10-21
EP1985631A1 (de) 2008-10-29
CA2684834A1 (en) 2008-10-30
DK2150561T3 (da) 2011-12-19
WO2008129422A1 (en) 2008-10-30
AR066132A1 (es) 2009-07-22
JP2010524453A (ja) 2010-07-22
KR20100017142A (ko) 2010-02-16
PL2150561T3 (pl) 2012-03-30
TW200914608A (en) 2009-04-01
CN101970481A (zh) 2011-02-09
AU2008240663A1 (en) 2008-10-30
WO2008129422A8 (en) 2009-11-19
ES2376022T3 (es) 2012-03-08
EP2150561B1 (de) 2011-10-26
US8802620B2 (en) 2014-08-12
US20100197578A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
ATE530575T1 (de) Demannosylierter rekombinanter faktor viii zur behandlung von patienten mit hämophilie a
EP3861968C0 (de) Vorrichtungen zur behandlung von schlafapnoe
ATE533518T1 (de) Resorbierbare polyetherester zur herstellung von medizinischen implantaten
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
EP2195069A4 (de) Vorrichtung zur behandlung von wunden mit unterdruck
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP2249752C0 (de) Vorrichtung zur behandlung von adipositas
IL209719A0 (en) Fviii muteins for treatment of von willebrand disease
EP2121110A4 (de) Biokompatible wundauflage
EP2442770A4 (de) Biegsamer medizinischer verband mit selbsttragendem substrat
DE602008004889D1 (de) Verfahren zur herstellung von ethylenoxid und ethylenglykol
EP2579936A4 (de) Magensonde zur behandlung von adipositas
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
EP2154147A4 (de) Gekürztes l1-protein des humanen papillomavirus 16
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DK2310043T4 (da) Faktor VIII samt von Willebrand faktor til behandling af koagulationsdefekt in-duceret af trombocythæmmere
EP2249765A4 (de) Dapson zur behandlung von rosascea
EP2767282A4 (de) Verwendung von glutarylhistamin zur behandlung von atemwegsinfektionen
EP2340039A4 (de) Verwendung von il-20-antagonisten zur behandlung von rheumatioder arthritis und osteoporose
DK2149372T3 (da) Anvendelse af opioider af metadongruppen til behandling af patienter med resistent cancer
ATE516805T1 (de) Medikament zur behandlung von endometriose
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
EP2164517A4 (de) Il-18 und protein-kinase-r-hemmung zur behandlung von copd

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2150561

Country of ref document: EP